- Companies
- PetMeds
PetMeds Valuation Multiples
PetMeds is valued at $26M as of October 2026, a 0.1x revenue multiple. In the last 12 months, PetMeds revenue was $163M.
PetMeds Overview
About PetMeds
PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.
Founded
1996
HQ
Employees
189
Website
Financials (LTM)
EV
$14M
Valuation Multiples
Start free trialPetMeds Financials
PetMeds reported last 12-month revenue of $163M.
In the same LTM period, PetMeds generated had net loss of ($32M).
Revenue (LTM)
PetMeds P&L
In the most recent fiscal year, PetMeds reported revenue of $179M and EBITDA of ($48M).
PetMeds is unprofitable as of last fiscal year, with gross margin of 28%, EBITDA margin of (27%), and net margin of (32%).
Financial data powered by Morningstar, Inc.
PetMeds Stock Performance
PetMeds has current market cap of $26M, and enterprise value of $14M.
Market Cap Evolution
PetMeds' stock price is $1.22.
PetMeds share price decreased by 11.6% in the last 30 days, and by 52.5% in the last year.
PetMeds has an EPS (earnings per share) of $-2.64.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14M | $26M | 1.7% | -11.6% | -37.4% | -52.5% | $-2.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPetMeds Valuation Multiples
PetMeds trades at 0.1x EV/Revenue multiple, and (0.3x) EV/EBITDA.
EV / Revenue (LTM)
PetMeds Financial Valuation Multiples
As of October 16, 2026, PetMeds has market cap of $26M and EV of $14M.
PetMeds has a P/E ratio of (0.8x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PetMeds Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


PetMeds Margins & Growth Rates
PetMeds decreased revenue by 17% and EBITDA by 100% in the last fiscal year.
In the most recent fiscal year, PetMeds reported gross margin of 28%, EBITDA margin of (27%), and net margin of (32%).
PetMeds Margins
PetMeds Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
PetMeds Operational KPIs
PetMeds' revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.6M for the same period.
PetMeds' Rule of 40 is (20%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PetMeds' Rule of X is (39%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
PetMeds Competitors
PetMeds competitors include Nomadar, 111, Vetted Assets, Sosandar, Desenio Group, Senshukai, Hamee, Bezvavlasy, SC Ropharma and Mene.
Most PetMeds public comparables operate across Consumer E-commerce, Pet Care, Pharmacies, Vertical E-commerce and PetTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $922K | ($3M) | 30.8x | - | (10.1x) | - | |||
| $1.9B | $3M | 0.0x | 0.0x | 14.6x | - | |||
| $13M | $7M | 2.5x | 1.4x | 4.4x | 58.3x | |||
| $56M | $2M | 0.4x | 0.4x | 12.0x | 7.4x | |||
| $74M | ($19M) | 0.3x | - | (1.1x) | - | |||
| $266M | $29M | - | - | - | - | |||
| $139M | $10M | 0.4x | 0.3x | 4.9x | 4.4x | |||
| $44M | $928K | 0.7x | - | 32.0x | - | |||
This data is available for Pro users. Sign up to see all PetMeds competitors and their valuation data. Start Free Trial | ||||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PetMeds
| When was PetMeds founded? | PetMeds was founded in 1996. |
| Where is PetMeds headquartered? | PetMeds is headquartered in United States. |
| How many employees does PetMeds have? | As of today, PetMeds has over 189 employees. |
| Who is the CEO of PetMeds? | PetMeds' CEO is Jeffrey Allen Willard. |
| Is PetMeds publicly listed? | Yes, PetMeds is a public company listed on Nasdaq. |
| What is the stock symbol of PetMeds? | PetMeds trades under PETS ticker. |
| When did PetMeds go public? | PetMeds went public in 1997. |
| Who are competitors of PetMeds? | PetMeds main competitors include Nomadar, 111, Vetted Assets, Sosandar, Desenio Group, Senshukai, Hamee, Bezvavlasy, SC Ropharma, Mene. |
| What is the current market cap of PetMeds? | PetMeds' current market cap is $26M. |
| What is the current revenue of PetMeds? | PetMeds' last 12 months revenue is $163M. |
| What is the current revenue growth of PetMeds? | PetMeds revenue growth (NTM/LTM) is (7%). |
| What is the current EV/Revenue multiple of PetMeds? | Current revenue multiple of PetMeds is 0.1x. |
| Is PetMeds profitable? | No, PetMeds is not profitable. |
| What is the current net income of PetMeds? | PetMeds' last 12 months net income is ($32M). |
| How many companies PetMeds has acquired to date? | PetMeds hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies PetMeds has invested to date? | PetMeds hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to PetMeds
Lists including PetMeds
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




